Item 8.01. Other Information

On January 27, 2021, Surface Ophthalmics, Inc. ("Surface") issued a press release (the "Surface PR") announcing the first patient dosed in a head-to-head phase II trial for its drug candidate SURF-100 (mycophenolate sodium and betamethasone in Klarity® vehicle) for the treatment of chronic dry eye disease. The head-to-head study will compare SURF-100 against leading on-market competitors lifitegrast ophthalmic solution 5% (marketed as Xiidra®) and cyclosporine ophthalmic emulsion 0.05% (marketed as Restasis®).

Harrow Health, Inc. currently owns three million five hundred thousand (3,500,000) shares of Surface common stock, which is approximately 30% of the issued and outstanding voting interests of Surface, along with a mid-single digit royalty right on net sales of SURF-100.

The foregoing is only a brief description of the Surface PR, does not purport to be a complete description of the Surface PR and is qualified in its entirety by reference to the full text of the document, which is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

All trademarks referenced in this Current Report on Form 8-K and the Surface PR are the property of their respective owners.

Item 9.01. Financial Statements and Exhibits





(d) Exhibits



Item   Description

99.1     Surface Ophthalmics Press Release Date January 27, 2021

© Edgar Online, source Glimpses